Elite Pharmaceuticals Inc (ELTP)

[Couch]

Abuse-Deterrent Formulations: One Tool in the Opioid-Abuse Epidemic

http://www.pharmacytimes.com/publications/issue/2017/august2017/abusedeterrent-formulations-one-tool-in-the-opioidabuse-epidemic

ADFs come in a variety of different forms (Table 24,8). The FDA requires manufacturers to study newly developed ADFs, comparing each with the previously approved product in laboratory, pharmacokinetic, and postmarketing studies.4 Proponents of increased use indicate that ADFs raise the likelihood that people with legitimate needs for opioids can obtain the drugs they need. They also indicate that ADF use decreases the chance that physicians and pharmacists will face civil and criminal liability suits related to overdose-related deaths. Proponents also point out that successful ADFs reduce the likelihood that states will need to implement other, more labor-intensive monitoring interventions.

ADF technology is new and evolving. Large, postmarketing studies comparing specific products with conventional opioids are starting to be published and indicate that nonmedical use is lower with ADFs,8 along with studies that look at multiple ADFs and their downstream impact.6,11,12